PhytoHealth Corp.

TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining Astragalus Polysaccharides (PG2®Lyo. Injection) with standard concurrent chemoradiotherapy (CCRT) significantly improves survival rates for patients with advanced esophageal cancer. The study enrolled 38 patients with stage IIb to IIIb esophageal cancer. Participants were randomly assigned to receive either CCRT alone or CCRT combined with PG2, a proprietary extract of Astragalus membranaceus roots developed by PhytoHealth Corporation. Results showed that patients who received PG2 in addition to CCRT experienced significantly longer overall survival compared to those who received CCRT alone. Furthermore, the combination therapy resulted in a higher tumor objective response rate. The study also found that PG2 helped strengthen the immune system by modulating the tumor immune microenvironment (TIME) and enhancing the suppression of tumor growth. 'These findings offer a new hope for patients with esophageal cancer,'' said Dr. Wen-Chieh Huang, Chief of Division of Thoracic Surgery at Mackay Memorial Hospital, Taiwan and the Principal Investigator of the clinical trial for PG2, a drug for cancer-related fatigue (CRF) relief developed by PhytoHealth Corporation, Taiwan. "PG2 has the potential to become a valuable addition to the standard treatment regimen, and can achieve improved patient outcomes.'' The data will be presented as a poster at the prestigious 2024 ESMO Congress. [ESMO abstract link]. Dr. Huang noted that treatment options for esophageal cancer patients are relatively limited compared to those for other cancers. However, this study has shown that PG2 combination therapy can reduce inflammation markers in the blood, decrease the differentiation of macrophages towards the M2 type, and even help shrink tumors while improving survival rates. This represents a significant breakthrough in the treatment of esophageal cancer. Dr. Huang further added that esophageal cancer patients often face tremendous challenges during treatment, with many unable to complete their therapy. However, by incorporating CRF medication, most patients were able to regain their strength, complete the full courses of cancer treatment, and achieve the expected therapeutic effects. Esophageal cancer is a challenging disease with high recurrence rates and poor survival outcomes. PG2, previously established as a treatment for cancer-related fatigue (already approved by Taiwan Food and Drug Administration) has shown promise as a potential treatment enhancer. This latest discovery marks a significant advancement in the ongoing battle against this challenging cancer. About PhytoHealth Corporation PhytoHealth Corporation is a leader in the development and manufacturing of botanical medicine and natural health products based in Taiwan. With a focus on scientific research and innovation, PhytoHealth is committed to providing safe, effective, and high-quality products that support overall health and well-being. Contact: Alison [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- The "Neutropenia - Pipeline Insight, 2023" report has been added to ResearchAndMarkets.com's offering. The latest insights into the Neutropenia Pipeline landscape for the year 2023 have been comprehensively compiled, offering a detailed view on the ongoing advancements in Neutropenia therapeutics. This report provides an extensive overview of various drug profiles, ranging from clinical to nonclinical development stages, and presents an in-depth therapeutic assessment by product type, developmental stage, route of administration, and molecule type, along with a systematic evaluation of inactive pipeline products within this field. Global Coverage and In-depth Understanding of Neutropenia In response to the growing demand for insightful data on Neutropenia, the report spans global coverage, carefully analyzing over 15 companies and their drug candidates operating within the pipeline. Neutropenia, a critical condition marked by low levels of neutrophils, has profound implications for patient health and prospective treatments. This report sheds light on the pathophysiology, categorization, symptoms, and existing treatment modalities while also outlining the potential for groundbreaking therapies in the pipeline. Unveiling Emerging Therapeutic Candidates The document details an arrangement of promising pharmacological innovations, including the exploration of diverse clinical trials, mechanisms of action, and prospective NDA approvals. Particular attention is given to Mavorixafor by X4 Pharmaceuticals, which has shown robust responses in Phase 1b clinical trials, and AKT-011 by AKTHELIA, a candidate that aims to reduce bacterial translocation. Robust Pipeline Assessment and Therapeutic Analysis With an emphasis on the various phases of drug development, the report encapsulates drugs at different stages, encompassing Phase III down to Discovery-stage candidates. Therapeutic assessments span across various modalities and product types, presenting a vast array of potential interventions for Neutropenia. Driving Forces Behind Advancements in Neutropenia Treatments The document delves into the strategical landscape, highlighting the collaborations, mergers, and acquisitions that shape the Neutropenia therapeutic space. With a lens on influential entities in the sector, the report assesses the current treatment scenario and the emerging therapies, addressing the unmet needs within the Neutropenia therapeutic domain. New Insights Provide Direction for Stakeholders and Healthcare Professionals This up-to-date Neutropenia pipeline insight report serves as a pivotal resource for stakeholders and healthcare professionals, aiming to foster informed decision-making and strategic planning. By assessing the pipeline product profiles and gauging the impact of drugs currently in development, the publication provides a road map for navigating the intricate landscape of Neutropenia therapeutics and underscores the urgency and potential of innovative treatments in this crucial field. Key Player Profiles X4 Pharmaceuticals AKTHELIA Spectrum Pharmaceuticals CSPC ZhongQi Pharmaceutical Technology Mabwell (Shanghai) Bioscience EmendoBio PhytoHealth Corporation Xiamen Amoytop Biotech For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets